Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Total Current Liabilities: 2019-2025

Historic Total Current Liabilities for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $82.3 million.

  • Nurix Therapeutics' Total Current Liabilities fell 4.57% to $82.3 million in Q3 2025 from the same period last year, while for Aug 2025 it was $82.3 million, marking a year-over-year decrease of 4.57%. This contributed to the annual value of $95.9 million for FY2024, which is 10.23% up from last year.
  • As of Q3 2025, Nurix Therapeutics' Total Current Liabilities stood at $82.3 million, which was up 8.91% from $75.6 million recorded in Q2 2025.
  • Nurix Therapeutics' Total Current Liabilities' 5-year high stood at $95.9 million during Q4 2024, with a 5-year trough of $46.8 million in Q2 2021.
  • Its 3-year average for Total Current Liabilities is $80.4 million, with a median of $82.3 million in 2025.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 55.12% in 2022, then dropped by 8.90% in 2023.
  • Over the past 5 years, Nurix Therapeutics' Total Current Liabilities (Quarterly) stood at $66.3 million in 2021, then grew by 6.64% to $70.7 million in 2022, then grew by 23.07% to $87.0 million in 2023, then increased by 10.23% to $95.9 million in 2024, then decreased by 4.57% to $82.3 million in 2025.
  • Its last three reported values are $82.3 million in Q3 2025, $75.6 million for Q2 2025, and $90.0 million during Q1 2025.